Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer
Open accessThe DOI matches its Crossref record; 153 of the 161 references it cites were found in a registry or an index; 18 of the 135 sources its claims cite were checked for support.
Abstract
Aminolevulinic acid (ALA) is an endogenous metabolite normally formed in the mitochondria from succinyl-CoA and glycine. Conjugation of eight ALA molecules yields protoporphyrin IX (PpIX) and finally leads to formation of heme. Conversion of PpIX to its downstream substrates requires the activity of a rate-limiting enzyme ferrochelatase. When ALA is administered externally the abundantly produced PpIX cannot be quickly converted to its final product - heme by ferrochelatase and therefore accumulates within cells. Since PpIX is a potent photosensitizer this metabolic pathway can be exploited in photodynamic therapy (PDT). This is an already approved therapeutic strategy making ALA one of the most successful prodrugs used in cancer treatment.
Overview
CoChat Summary
## TL;DR
This paper is a review of aminolevulinic acid (ALA) as a prodrug for photodynamic therapy (PDT) in cancer, explaining how exogenous ALA leads to protoporphyrin IX (PpIX) accumulation and selective tumor killing after light exposure. It argues that ALA-PDT is a highly promising, clinically approved strategy, but its effectiveness is limited by poor penetration, pain, light depth, and variable PpIX accumulation.
## Key findings
- Exogenous ALA bypasses normal heme-regulated control, causing PpIX to accumulate because ferrochelatase cannot convert it to heme quickly enough; light exposure after about 4–6 hours activates PpIX and generates cytotoxic singlet oxygen.
- Tumor selectivity is linked to heme-pathway differences: decreased ferrochelatase activity, limited iron availability, and increased activity of PpIX-producing enzymes such as ALAD, UROD, and PBGD contribute to higher PpIX in tumors than in normal cells.
- Reported clinical outcomes include 50%–100% complete responses for superficial basal cell carcinoma, 43% recurrence at 60 months, 100% response with no recurrence after 18 months in cutaneous T-cell lymphoma, and 68%–75% complete response after single MAL-PDT for actinic keratosis.
- The paper states that at least 77 ALA modifications and carriers have been reported to improve delivery, reflecting strong interest in overcoming ALA’s limited skin and tissue penetration.
## Methods
- Narrative review of the literature on ALA metabolism, pharmacokinetics, preclinical PDT studies, clinical indications, and ALA derivatives.
- Synthesizes prior experimental and clinical studies in multiple systems, including cell lines, mouse and rat models, and human clinical trials.
- Main analysis is qualitative: it compares reported mechanisms, delivery strategies, and treatment outcomes rather than presenting a new dataset or original statistical analysis.
## Limitations
- The paper states that ALA-PDT is limited by light hypersensitivity, inefficiency for large or metastatic tumors, pain during treatment, and limited tissue penetration.
- It also states that topical and even systemic ALA penetrate tissues only poorly, restricting efficacy; for topical use, PpIX fluorescence is seen only to a depth of 0.3 to 0.6 mm.
- Evident from the text: this is a review, so its conclusions depend on prior studies and are not based on a single controlled experiment or newly collected patient cohort.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
17 Valid · 3 Not valid · 72 Not checked · 20 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Enhanced activity of enzymes leading to production of PpIX, such as ALAD [43], UROD [43], or PBGD [38,43,44] has also been observed in tumor cells.”
§ Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer > 2. Metabolism of ALA > 2.4. Selectivity of PpIX Accumulation in Tumor Tissue in Response to ALA Administration
What the sources say
- Not checked — no full text of the sourcecites [43] Navone, 1990, Heme biosynthesis in human breast cancer--mimetic "in vitro" studies and some heme enzymic activity levels, Int. J. Biochem. source
- Partly supportedcites [38] Hinnen, 1998, Biochemical basis of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation: A study in patients with (pre)malignant lesions of the oesophagus, Br. J. Cancer sourceExperimental — accuracy not yet measured
The Discussion (p. 681) reports increased PBG-D activity in malignant and premalignant oesophageal tissue compared with normal squamous epithelium, supporting the PBGD part of the citation. The paper reports measuring PBG-D and ferrochelatase, but the passages found do not report enhanced ALAD or UROD activity in tumor cells. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [44] Kondo, 1993, Heme-biosynthetic enzyme activities and porphyrin accumulation in normal liver and hepatoma cell lines of rat, Cell. Biol. Toxicol. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“PpIX has been found to preferentially accumulate in tumor as compared with normal cells.”
§ Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer > 2. Metabolism of ALA > 2.4. Selectivity of PpIX Accumulation in Tumor Tissue in Response to ALA Administration
What the sources say
- Supportedcites [38] Hinnen, 1998, Biochemical basis of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation: A study in patients with (pre)malignant lesions of the oesophagus, Br. J. Cancer source
The Discussion (p. 682) says the study's results provide evidence for selective PPIX accumulation between normal and neoplastic tissue of the oesophagus. This supports the claim that preferential tumour accumulation has been found, without implying it occurs in every tumour type. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [39] Krieg, 2000, Cell-type specific protoporphyrin IX metabolism in human bladder cancer in vitro, Photochem. Photobiol. doi:10.1562/0031-8655(2000)072
- Not checked — no full text of the sourcecites [40] Hefti, 2011, Susceptibility to 5-aminolevulinic acid based photodynamic therapy in WHO I meningioma cells corresponds to ferrochelatase activity, Photochem. Photobiol. source
- Not checked — no full text of the sourcecites [41] Ohgari, 2005, Mechanisms involved in delta-aminolevulinic acid (ALA)-induced photosensitivity of tumor cells: Relation of ferrochelatase and uptake of ALA to the accumulation of protoporphyrin, Biochem. Pharmacol. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In 1987 ALA was used for the first time in photodynamic therapy as a porphyrin precursor for selective elimination of erythroleukaemic cells [89].”
§ Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer > 6. Preclinical Studies with ALA
What the sources say
- Partly supportedcites [89] Malik, 1987, Destruction of erythroleukaemic cells by photoactivation of endogenous porphyrins, Br. J. Cancer sourceExperimental — accuracy not yet measured
The Summary (p. 589) reports that 5-ALA stimulated porphyrin synthesis in Friend erythroleukaemic cells and that light exposure selectively destroyed the cells. The paper does not establish that this was the first use of ALA in photodynamic therapy; that priority claim is unsupported by our copy. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Enhancement of PDT effects has been also observed after removal of iron with different iron-chelating substances such as desferrioxamine [51] or CP94 [52].”
§ Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer > 2. Metabolism of ALA > 2.5. Modifications of Heme Biosynthetic Pathway and Its Influence on ALA-PDT
What the sources say
- Supportedcites [51] Tan, 1997, Enhancement of photodynamic therapy in gastric cancer cells by removal of iron, Gut source
The Abstract (p. 1) of Tan et al. (1997) states 'PDT using ALA can be improved by removal of available iron with desferrioxamine', with 200 µmolar desferrioxamine trebling PPIX accumulation and low doses (0–30 µmolar) reducing cell viability after light exposure; the Discussion (QUANTITATION OF PORPHYRIN section) adds that adding iron abrogated the desferrioxamine effect, supporting iron removal as the mechanism. This covers the part of the citing sentence offered to this source (desferrioxamine); CP94 is carried on a separate citation [52] and is not mentioned anywhere in our copy. The source's demonstration is in an in vitro gastric cancer cell line (AGA) with ALA/PDT, and it notes a paradoxical protective effect at higher desferrioxamine doses ('J'-shaped curve, Conclusion), so the enhancement is dose-related rather than unconditional. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [52] Blake, 2010, The hydroxypyridinone iron chelator CP94 can enhance PpIX-induced PDT of cultured human glioma cells, Photochem. Photobiol. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Compared with cryotherapy for actinic keratosis MAL-PDT was found to have a better or similar effectiveness (complete response rate 68%–75% after single treatment) [129,130].”
§ Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer > 7. Clinical Indications for ALA and Its Esters
What the sources say
- Partly supportedcites [129] Tarstedt, 2005, A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp, Acta Derm. Venereol. sourceExperimental — accuracy not yet measured
Our copy of Tarstedt et al. (Abstract) shows this was a head-to-head comparison of two MAL-PDT schedules (single treatment vs two treatments 1 week apart) in 211 patients with thin-to-moderately thick actinic keratoses of the face and scalp; there is no cryotherapy arm and no cryotherapy comparison anywhere in the text we hold (searched: cryotherapy, liquid nitrogen, freezing, comparison with previous studies). The single-treatment complete response figures it does report — 93% (87–97%) for thin lesions and 70% (60–78%) for thicker lesions — only partly fall inside the 68%–75% range the citing sentence attributes, and the 'better or similar effectiveness compared with cryotherapy' claim is not supported by this source. (LLM, conf=0.70)
- Not checked — no full text of the sourcecites [130] Freeman, 2003, A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: A prospective, randomized study, J. Dermatolog Treat. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
43 more claims
Create a free account to see all 112 claims and to verify the 10 references still open.
- It may state two separate claims as one. 45
- Probably not a substantial claim. 29
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“ALA administered topically or systemically is non-selectively taken up into cells and metabolized into photosensitive PpIX by the resident enzyme machinery [8].”
From Photodynamic Therapy for Non-Melanoma Skin Cancers (2016) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer > 5. Comparison of ALA with Porphyrin-based Photosensitizers
“ALA is the only photosensitizer registered for topical use, particularly useful for the local treatment of superficial skin lesions.”
§ Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer > 7. Clinical Indications for ALA and Its Esters
“MAL was approved in the treatment of actinic keratosis and nonmelanoma skin cancers (basal cell carcinoma) in Australia, New Zealand and some European countries. MAL, administered in a form of a cream, 3 hours after application under occlusion is activated with red light usually in a total dose of 75 J/cm2.”
Citations
Cites
Dougherty, T. J., Gomer, C. J., Henderson, B. W., Jori, G., Kessel, D., Korbelik, M., Moan, J., & Peng, Q. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.12.889 · Cited by 4,716
Gomer, C. J. (1988) · Cited by 4,174
Heme oxygenase: Function, multiplicity, regulatory mechanisms, and clinical applications
Maines, M. D. (1988) · The FASEB Journal · doi:10.1096/fasebj.2.10.3290025 · Cited by 1,707 · cited 1×
“HO exists in two izoforms, significantly different in their regulatory mechanism: HO-1 is an inducible form whereas HO-2 is expressed constitutively [27,28].”
BackgroundPhotodynamic therapy with endogenous protoporphyrin
Kennedy, J. C., Pottier, R. H., & Pross, D. C. (1990) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/1011-1344(90)85083-9 · Cited by 1,509 · cited 1×
“Since the very first topical application of ALA in the treatment of basal cell carcinoma in 1990 [8], the clinical use of ALA-PDT is still growing.”
BackgroundO’Connor, A. E., Gallagher, W. M., & Byrne, A. T. (2009) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2009.00585.x · Cited by 1,191
Kennedy (1992) · doi:10.1016/1011-1344(92)85108-7 · Cited by 1,166
5-Aminolevulinic Acid-Based Photodynamic Therapy: Principles and Experimental Research
Peng, Q., Berg, K., Moan, J., Kongshaug, M., & Nesland, J. M. (1997) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1997.tb08549.x · Cited by 615 · cited 2×
“Subsequent illumination of the tumor site with red light activates PpIX, triggers the oxidative damage and induces cytotoxicity [6].”
BackgroundStructure and Biodistribution Relationships of Photodynamic Sensitizers*
Boyle, R. W., & Dolphin, D. (1996) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1996.tb03093.x · Cited by 498
Biosynthesis of heme in mammals
Ajioka, R. S., Phillips, J. D., & Kushner, J. P. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.05.005 · Cited by 493 · cited 1×
“The synthesis of ALA is the first and rate-limiting step in the biosynthesis of heme [9-11].”
BackgroundOxygen Consumption and Diffusion Effects in Photodynamic Therapy
Foster, T. H., Murant, R. S., Bryant, R. G., Knox, R. S., Gibson, S. L., & Hilf, R. (1991) · Radiation Research · doi:10.2307/3577919 · Cited by 400
Cited by
BODIPY dyes in photodynamic therapy
Kamkaew, A., Lim, S. H., Lee, H. B., Kiew, L. V., Chung, L. Y., & Burgess, K. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35216h · Cited by 2,104
Wu, G., Zhang, J., Zhao, Q., Zhuang, W., Ding, J., Zhang, C., Gao, H., Pang, D., Pu, K., & Xie, H. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201913700 · Cited by 269
Photodynamic Therapy: A Compendium of Latest Reviews
Algorri, J. F., Ochoa, M., Roldán-Varona, P., Rodríguez-Cobo, L., & López-Higuera, J. M. (2021) · Cancers · doi:10.3390/cancers13174447 · Cited by 263
Dias, L. D., Blanco, K. C., Mfouo-Tynga, I. S., Inada, N. M., & Bagnato, V. S. (2020) · Journal of Photochemistry and Photobiology C: Photochemistry Reviews · doi:10.1016/j.jphotochemrev.2020.100384 · Cited by 251
Extracellular Metabolites from Industrial Microalgae and Their Biotechnological Potential
Liu, L., Pohnert, G., & Wei, D. (2016) · Marine Drugs · doi:10.3390/md14100191 · Cited by 193
“5-Aminolevulinic acid (ALA), which is a precursor of tetrapyrroles such as chlorophyll, haem, and vitamin B12, is used as a degradable insecticide and growth-promoting factor for plants [97].”
BackgroundPhotodynamic therapy and diagnosis: Principles and comparative aspects
Dobson, J., de Queiroz, G. F., & Golding, J. P. (2018) · The Veterinary Journal · doi:10.1016/j.tvjl.2017.11.012 · Cited by 162
“Photodynamic therapy (PDT) involves administration of a photosensitiser drug, or a pro-drug, which selectively accumulates in target cells, followed by local illumination of the lesion with visible light (Luksiene, 2003; Wachowska et al., 2011).”
Contribution of photodynamic therapy in wound healing: A systematic review
dos Reis, V. N., Lera‐Nonose, D. S. S. L., Oyama, J., Lalucci, M. P. D. P. S., Demarchi, I. G., Aristides, S. M. A., Teixeira, J. J. V., Silveira, T. G. V., & Lonardoni, M. V. C. (2017) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2017.12.015 · Cited by 178
Harnessing carbon monoxide-releasing platforms for cancer therapy
Zhou, Y., Yu, W., Cao, J., & Gao, H. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120193 · Cited by 149
Organoiridium Photosensitizers Induce Specific Oxidative Attack on Proteins within Cancer Cells
Zhang, P., Chiu, C. K. C., Huang, H., Lam, Y. P. Y., Habtemariam, A., Malcomson, T., Paterson, M. J., Clarkson, G. J., O’Connor, P. B., Chao, H., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201709082 · Cited by 141
Photodynamic Therapy for Non-Melanoma Skin Cancers
Cohen, D., & Lee, P. (2016) · Cancers · doi:10.3390/cancers8100090 · Cited by 128
“ALA administered topically or systemically is non-selectively taken up into cells and metabolized into photosensitive PpIX by the resident enzyme machinery [8].”
BackgroundDeconvoluting heme biosynthesis to target blood-stage malaria parasites
Sigala, P. A., Crowley, J. R., Henderson, J. P., & Goldberg, D. E. (2015) · eLife · doi:10.7554/elife.09143 · Cited by 98
“Conventional PDT requires an external light source to photoactivate and kill ALA-stimulated cells (Juzeniene et al., 2007; Celli et al., 2010; Wachowska et al., 2011).”
BackgroundResultInfluentialPhotosensitizers for Two‐Photon Excited Photodynamic Therapy
Sun, Z., Zhang, L., Wu, F., & Zhao, Y. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201704079 · Cited by 119
Wang, J., Zhang, J., Shi, Y. P., Xu, C., Zhang, C., Wong, Y. K., Lee, Y. M., Krishna, S., He, Y., Lim, T. K., et al. (2017) · ACS Central Science · doi:10.1021/acscentsci.7b00156 · Cited by 114
Utility of Photodynamic Therapy in Dentistry: Current Concepts
Stájer, A., Kajári, S., Gajdács, M., Musah-Eroje, A., & Baráth, Z. (2020) · Dentistry Journal · doi:10.3390/dj8020043 · Cited by 135
“5 mm, so this method is only applicable for superficial lesions [39,71].”
BackgroundMethodInfluentialZhang, P., & Huang, H. (2018) · Dalton Transactions · doi:10.1039/c8dt03432j · Cited by 122
Photodynamic Therapy As a Promising Method Used in the Treatment of Oral Diseases
Prażmo, E. J., Mielczarek, A. B., Kwaśny, M., & Łapiński, M. (2016) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/32488 · Cited by 130
“Intralesional injections often cause significant pain to the patient and systemic administration may cause side-effects [35], such as headache, nausea, fatigue and paraesthesia [36, 37].”
BackgroundPhotodynamic Therapy and the Biophysics of the Tumor Microenvironment
Sorrin, A. J., Ruhi, M. K., Ferlic, N. A., Karimnia, V., Polacheck, W. J., Celli, J. P., Huang, H., & Rizvi, I. (2020) · Photochemistry and Photobiology · doi:10.1111/php.13209 · Cited by 109
“This includes decreased FECH activity and increased CPO activity, which increases the production of PpIX and limits its conversion to heme, leading to increased accumulation of the PS in target tissue (184).”
BackgroundPhotodynamic therapy in wound healing in vivo: a systematic review
Oyama, J., Milaré, Á. C. F. H. R., Lera‐Nonose, D. S. S. L., dos Reis, V. N., Demarchi, I. G., Aristides, S. M. A., Teixeira, J. J. V., Silveira, T. G. V., & Lonardoni, M. V. C. (2020) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2020.101682 · Cited by 112
Drug Delivery Systems for Phthalocyanines for Photodynamic Therapy
Rak, J., POUCKOVA, P., Beneš, J., & Větvička, D. (2019) · Anticancer Research · doi:10.21873/anticanres.13475 · Cited by 105
Mechanisms for Tuning Engineered Nanomaterials to Enhance Radiation Therapy of Cancer
Clement, S., Campbell, J. M., Deng, W., Guller, A., Nisar, S., Liu, G., Wilson, B. C., & Goldys, E. M. (2020) · Advanced Science · doi:10.1002/advs.202003584 · Cited by 96
Yan, L., Amirshaghaghi, A., Huang, D., Miller, J. M., Stein, J. M., Busch, T. M., Cheng, Z., & Tsourkas, A. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201707030 · Cited by 96
Wang, Y., Yang, M., Qian, J., Xu, W., Wang, J., Hou, G., Ji, L., & Suo, A. (2018) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2018.09.035 · Cited by 94
Fluorescence‐guided surgery for high‐grade gliomas
Lakomkin, N., & Hadjipanayis, C. G. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.25154 · Cited by 91
“use for FGS, and its limited side effect profile relative to other photosensitizers.(36) In vitro studies have revealed that 5‐ALA‐mediated”
BackgroundFluorescence guidance in urologic surgery
(2012) · doi:10.1097/mou.0b013e3283501869 · Cited by 83
“After 5-ALA administration, the abundantly produced PpIX cannot be rapidly converted into heme and will therefore accumulate intracellularly, leading to a higher signal intensity in proliferative (tumor) tissue [28].”
BackgroundPhotodynamic Antimicrobial Chemotherapy
Phoenix, D. A., Dennison, S. R., & Harris, F. (2014) · Wiley eBooks · doi:10.1002/9783527676132.ch10 · Cited by 85
Pignatelli, P., Umme, S., D’Antonio, D. L., Piattelli, A., & Curia, M. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108964 · Cited by 92
“A high degree of selectivity is the best mode adopted by PDT and it is achieved by the combination of visible light and photosensitizing agents, which, when applied in the presence of molecular oxygen, lead to the formation of cytotoxic intermediates that kill tumor cells [17].”
Wu, J., Han, H., Jin, Q., Li, Z., Li, H., & Ji, J. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b15853 · Cited by 80
Recent advances in production of 5-aminolevulinic acid using biological strategies
Kang, Z., Ding, W., Xu, G., Liu, Q., Du, G., & Chen, J. (2017) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-017-2366-7 · Cited by 75
Dutta, S., & Bhat, N. S. (2021) · ChemCatChem · doi:10.1002/cctc.202100032 · Cited by 78
He, L., Zhang, M.-F., Pan, Z., Wang, K., Zhao, Z.-J., Li, Y., & Mao, Z. (2019) · Chemical Communications · doi:10.1039/c9cc04871e · Cited by 64
Photosensitizers in photodynamic therapy: An advancement in cancer treatment
Oluwajembola, A. M., Cleanclay, W. D., Onyia, A. F., Chikere, B., Zakari, S., Ndifreke, E., & Campos, O. C. D. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101715 · Cited by 80
Fiorito, V., Allocco, A. L., Petrillo, S., Gazzano, E., Torretta, S., Marchi, S., Destefanis, F., Pacelli, C., Audrito, V., Provero, P., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109252 · Cited by 58
“Food and Drug Administration (FDA)-approved drugs expected to inhibit/ enhance heme synthesis and heme export are already available (Wachowska et al., 2011; Webber et al., 1999; Stein et al., 2017) and could be used to interfere with cell metabolic adaptation in various disease types.”
BackgroundPhotodynamic Therapy for Glioblastoma: Illuminating the Path toward Clinical Applicability
Bhanja, D., Wilding, H., Baroz, A., Trifoi, M., Shenoy, G., Slagle-Webb, B., Hayes, D., Soudagar, Y., Connor, J., & Mansouri, A. (2023) · Cancers · doi:10.3390/cancers15133427 · Cited by 59
“While not intrinsically fluorescent, 5-ALA is enzymatically converted to PpIX, a photosensitizer that can also be endogenously produced, by the heme biosynthesis pathway [12,13].”
BackgroundYang, Y., Gao, N., Hu, Y., Jia, C., Chou, T., Du, H., & Wang, H. (2015) · Therapeutic Delivery · doi:10.4155/tde.14.115 · Cited by 58
Tewari, K. M., & Eggleston, I. M. (2018) · Photochemical & Photobiological Sciences · doi:10.1039/c8pp00362a · Cited by 57
Photodynamic viral inactivation: Recent advances and potential applications
Willis, J. A., Cheburkanov, V. D., Kassab, G., Soares, J. M., Blanco, K. C., Bagnato, V. S., & Yakovlev, V. V. (2021) · Applied Physics Reviews · doi:10.1063/5.0044713 · Cited by 61
Lamberti, M. J., Vittar, N. B. R., da Silva, F. D. C., Ferreira, V. F., & Rivarola, V. A. (2013) · Phytomedicine · doi:10.1016/j.phymed.2013.04.018 · Cited by 50
Advanced Near‐Infrared Light‐Responsive Nanomaterials as Therapeutic Platforms for Cancer Therapy
Chien, Y., Chan, K. K., Anderson, T., Kong, K. V., Ng, B. K., & Yong, K. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800090 · Cited by 52
Wu, J., Lin, Y., Li, H., Jin, Q., & Ji, J. (2016) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2016.09.012 · Cited by 49
Gotardo, F., Cocca, L. H. Z., Acunha, T. V., Longoni, A., Toldo, J. M., Gonçalves, P. F. B., Iglesias, B. A., & Boni, L. D. (2017) · Chemical Physics Letters · doi:10.1016/j.cplett.2017.02.055 · Cited by 48
A review of BF-200 ALA for the photodynamic treatment of mild-to-moderate actinic keratosis
Reinhold, U. (2017) · Future Oncology · doi:10.2217/fon-2017-0247 · Cited by 46
Osaki, T., Yokoe, I., Sunden, Y., Ota, U., Ichikawa, T., Imazato, H., Ishii, T., Takahashi, K., Ishizuka, M., Tanaka, T., et al. (2019) · Cancers · doi:10.3390/cancers11040495 · Cited by 50
“5-Aminolevulinic acid (5-ALA), a commonly used photosensitizer in PDD and PDT, constitutes a precursor of the established photosensitizer protoporphyrin IX (PpIX) that is converted in situ to PpIX via the heme biosynthetic pathway [8,9].”
BackgroundTran, T. T., Mu, A., Adachi, Y., Adachi, Y., & Taketani, S. (2014) · Photochemistry and Photobiology · doi:10.1111/php.12290 · Cited by 48
Host-guest complexes – Boosting the performance of photosensitizers
Sowa, A., & Voskuhl, J. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119595 · Cited by 44
Photodynamic therapy: Overview and mechanism of action
Austin, E., Wang, J. Y., Ozog, D., Zeitouni, N. E., Lim, H. W., & Jagdeo, J. R. (2025) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2025.02.037 · Cited by 66
NIR-activated multifunctional agents for the combined application in cancer imaging and therapy
Repetowski, P., Warszyńska, M., & Dąbrowski, J. M. (2024) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2024.103356 · Cited by 48
The abscopal effects of sonodynamic therapy in cancer
Collins, V. G., Hutton, D. L., Hossain-Ibrahim, K., Joseph, J. A., & Banerjee, S. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02898-y · Cited by 51
“When 5-ALA is given exogenously (increasing its level above the biological baseline), abundantly produced PpIX cannot be quickly converted into haem, and therefore accumulates within cells [32].”
Radunović, M., Petrini, M., Tovilović, T. V., Iezzi, G., Lodovico, S. D., Piattelli, A., & D’Ercole, S. (2020) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2020.111826 · Cited by 40
Predictors and Limitations of the Penetration Depth of Photodynamic Effects in the Rodent Brain
Inglut, C. T., Gaitan, B., Najafali, D., Lopez, I. A., Connolly, N. P., Orsila, S., Perttilä, R., Woodworth, G. F., Chen, Y., & Huang, H. (2019) · Photochemistry and Photobiology · doi:10.1111/php.13155 · Cited by 37
“pathway compared to healthy tissues (31).”
Xu, H., Liu, Mei, S., Yao, Wang, Wang, Li, L., & Zhang, Z. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s33261 · Cited by 43
“36 Given this dual selectivity for tumor cells, ALA-GNPs should have better targeting effects than other photosensitive drugs.”
Intracellular Dual Fluorescent Lightup Bioprobes for Image-Guided Photodynamic Cancer Therapy
Han, H., Jin, Q., Wang, H., Teng, W., Wu, J., Tong, H., Chen, T., & Ji, J. (2016) · Small · doi:10.1002/smll.201600950 · Cited by 38
Optimization of 5-aminolevulinic acid-based photodynamic therapy protocol for breast cancer cells
Eskiler, G. G., Özkan, A. D., Kucukkara, E. S., Kamanlı, A. F., Günoğlu, B., & Yıldız, M. Z. (2020) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2020.101854 · Cited by 37
Bleomycin enhances the efficacy of sonodynamic therapy using aluminum phthalocyanine disulfonate
Osaki, T., Yokoe, I., Uto, Y., Ishizuka, M., Tanaka, T., Yamanaka, N., Kurahashi, T., Azuma, K., Murahata, Y., Tsuka, T., et al. (2015) · Ultrasonics Sonochemistry · doi:10.1016/j.ultsonch.2015.07.013 · Cited by 36
Increased DNA repair capacity augments resistance of glioblastoma cells to photodynamic therapy
Ghahe, S. S., Kosicki, K., Wojewódzka, M., Majchrzak, B., Fogtman, A., Iwanicka‐Nowicka, R., Ciuba, A., Koblowska, M., Kruszewski, M. K., Tudek, B., et al. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103136 · Cited by 35
Makuch, S., Dróżdż, M., Makarec, A., Ziolkowski, P. P., & Woźniak, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179845 · Cited by 40
“However, this compound can be further metabolized by the cells into protoporphyrin IX (PpIX), which may be subsequently activated by visible light [21].”
BackgroundWu, G., Zhang, J., Zhao, Q., Zhuang, W., Ding, J., Zhang, C., Gao, H., Pang, D., Pu, K., & Xie, H. (2019) · Angewandte Chemie · doi:10.1002/ange.201913700 · Cited by 34
Nanobiomaterials for Cancer Therapy
Tao, W., & Mei, L. (2017) · Wiley eBooks · doi:10.1002/9783527698646.ch13 · Cited by 32
Recent strategies to design vascular theranostic nanoparticles
Gupta, M. K., Lee, Y., Boire, T. C., Lee, J.-B., Kim, W. S., & Sung, H. (2017) · Nanotheranostics · doi:10.7150/ntno.18531 · Cited by 32
“5-Aminolevulinic acid (ALA) is an endogenous photodynamic metabolite, which transforms into an active photosensitizer porphyrin IX (PPIX) inside cells through a cellular heme biosynthetic pathway [33].”
BackgroundLuminol as the light source for in situ photodynamic therapy
Chen, T.-C., Huang, L., Liu, C.-C., Chao, P.-J., & Lin, F. (2012) · Process Biochemistry · doi:10.1016/j.procbio.2012.06.025 · Cited by 35
Photodynamic Diagnosis and Therapy for Peritoneal Carcinomatosis: Emerging Perspectives
Xu, S., Bulin, A., Hurbin, A., Elleaume, H., Coll, J., & Broekgaarden, M. (2020) · Cancers · doi:10.3390/cancers12092491 · Cited by 33
“In addition, the buildup of PpIX can be attributed to the elevated activity of the heme synthesis pathway in combination with the reduced activity of ferrochelatase, which normally catalyzes the final conversion of PpIX into heme [19].”
Combination of photodynamic therapy and temozolomide on glioma in a rat C6 glioma model
Zhang, X., Guo, M., Shen, L., & Hu, S. (2014) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2014.10.007 · Cited by 29
Zhang, P., Hu, Y., Ma, R., Li, L., & Lu, J. G. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb02638a · Cited by 29
Photodynamic therapy for glioblastoma: A light at the end of the tunnel
Miretti, M., Graglia, M. A. G., Suárez, A. I., & Prucca, C. G. (2023) · Journal of Photochemistry and Photobiology · doi:10.1016/j.jpap.2023.100161 · Cited by 31
The Dark Side: Photosensitizer Prodrugs
Sansaloni-Pastor, S., Bouilloux, J., & Lange, N. (2019) · Pharmaceuticals · doi:10.3390/ph12040148 · Cited by 31
“The explained PPIX accumulation after 5-ALA supply occurs in healthy and cancer cells; nevertheless, some factors have been suggested to induce the differential PPIX accumulation observed between cancer and healthy cells [90]: (1) Availability of iron, (2) lower activity of ferrochelatase, (3) transferrin receptor exp…”
BackgroundBODIPY-based monofunctional Pt (II) complexes for specific photocytotoxicity against cancer cells
Qi, F., Yuan, H., Chen, Y., Guo, Y., Zhang, S., Liu, Z., He, W., & Guo, Z. (2021) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2021.111394 · Cited by 27
Magagnoli, L., Ciceri, P., & Cozzolino, M. G. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2369307 · Cited by 32
“Under irradiation with a 380–420 nm laser, PpIX emits red fluorescence, while intense irradiation (~635 nm) triggers a series of photochemical reactions that lead to the production of cytotoxic reactive oxygen species and eventual cell death [120].”
Functional Nucleic Acid Probe for Parallel Monitoring K+ and Protoporphyrin IX in Living Organisms
Cheng, H., Qiu, X., Zhao, X., Meng, W., Huo, D., & Wei, H. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b04936 · Cited by 27
(2018) · doi:10.15171/apb.2018.071 · Cited by 25
“When exogenous 5ALA is introduced into the cells, the concentration of protoporphyrin-IX (PpIX) increases during heme biosynthesis pathway.(23) This PpIX can act as a strong photosensitizer in photodynamic therapy (PDT).”
BackgroundChen, M., Zhou, A. E., & Khachemoune, A. (2023) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00829-w · Cited by 28
“One of the most successful and effective ALA derivatives is methyl ester (methyl-aminolevulinate, MAL) [44], in which the addition of a methyl group leads to greater lipophilicity and thus better tissue penetration [23].”
Mechanisms of Resistance to Photodynamic Therapy (PDT) in Vulvar Cancer
Mossakowska, B. J., Ghahe, S. S., Cysewski, D., Fabisiewicz, A., Tudek, B., & SIEDLECKI, J. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084117 · Cited by 28
“In cells, 5-ALA is converted in the heme biosynthetic pathway to protoporphyrin IX (PpIX), an actual PS (Figure 1) [6,7].”
BackgroundInfluentialPhoto-Responsive Supramolecular Micelles for Controlled Drug Release and Improved Chemotherapy
Ilhami, F. B., Peng, K.-C., Chang, Y.-S., Alemayehu, Y. A., Tsai, H., Lai, J., Chiao, Y., Kao, C., & Cheng, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010154 · Cited by 25
Current Photodynamic Therapy for Glioma Treatment: An Update
Aebisher, D., Przygórzewska, A., Myśliwiec, A., Dynarowicz, K., Krupka‐Olek, M., Bożek, A., Kawczyk‐Krupka, A., & Bartusik‐Aebisher, D. (2024) · Biomedicines · doi:10.3390/biomedicines12020375 · Cited by 26
Mohammadi, Z., Sazgarnia, A., Rajabi, O., & Toussi, M. S. (2016) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2016.1167697 · Cited by 24
Mitochondrial Heme Synthesis Enzymes as Therapeutic Targets in Vascular Diseases
Shetty, T., & Corson, T. W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01015 · Cited by 26
Kazemi, K. S., Kazemi, P., Mivehchi, H., Nasiri, K., Hoseini, S. S. E., Nejati, S. T., Bahrami, P. P., Golestani, S., & Nabi‐Afjadi, M. (2024) · Biological Procedures Online · doi:10.1186/s12575-024-00252-3 · Cited by 31
Recapitulation of Hypoxic Tumor–stroma Microenvironment to Study Photodynamic Therapy Implications
Lamberti, M. J., Vasconsuelo, A. B. M., Ferrara, M. G., & Vittar, N. B. R. (2020) · Photochemistry and Photobiology · doi:10.1111/php.13220 · Cited by 21
“, methyl-ALA, here Me-ALA), PpIX accumulates within cells and its excitation by red-light exposure leads to cellular damage (7,8).”
BackgroundPhotoactivated cell-killing involving a low molecular weight, donor–acceptor diphenylacetylene
Chisholm, D. R., Lamb, R., Pallett, T. L., Affleck, V., Holden, C. A., Marrison, J., O’Toole, P. J., Ashton, P. D., Newling, K., Steffen, A., et al. (2019) · Chemical Science · doi:10.1039/c9sc00199a · Cited by 20
Zhang, W., Wang, J., & Shan, C. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107195 · Cited by 26
Rosin, F. C. P., Teixeira, M. G., Pelissari, C., & Côrrea, L. (2018) · Photochemistry and Photobiology · doi:10.1111/php.13029 · Cited by 20
“mation of high levels of ROS, leading to cell death (5).”
BackgroundRole of Aminolevulinic Acid in Stress Adaptation and Crop Productivity
(2018) · doi:10.20546/ijcmas.2018.705.178 · Cited by 21
“…received wide attention due to its potential use as herbicide (Xu et al., 2015), insecticide (Yang et al., 2011), plant stimulator under different stress conditions (Kosar et al., 2015), antimicrobial drug (Malik et al., 1990) and photosensitizer for photodynamic therapy (Wachowska et al., 2011).”
BackgroundHeat shock protein 27 modulates autophagy and promotes cell survival after photodynamic therapy
Rodríguez, M. E., Arévalo, D. E., Sanabria, L. M., Carrión, F. D. C., Fanelli, M. A., & Rivarola, V. A. (2019) · Photochemical & Photobiological Sciences · doi:10.1039/c8pp00536b · Cited by 22
Potentiating anti-cancer chemotherapeutics and antimicrobials via sugar-mediated strategies
Mullapudi, S. S., Mitra, D., Li, M., Kang, E. T., Chiong, E., & Neoh, K. G. (2020) · Molecular Systems Design & Engineering · doi:10.1039/c9me00175a · Cited by 22
Monte Carlo modelling of daylight activated photodynamic therapy
Campbell, C. L., Wood, K., Valentine, R. M., Brown, C. T. A., & Moseley, H. (2015) · Physics in Medicine and Biology · doi:10.1088/0031-9155/60/10/4059 · Cited by 21
Joniová, J., Kazemiraad, C., Gerelli, E., & Wagnières, G. (2021) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2021.112347 · Cited by 24
White, B., Rossi, V. M., & Baugher, P. J. (2016) · Photomedicine and Laser Surgery · doi:10.1089/pho.2016.4091 · Cited by 22
Ebrahimi, S., Mirzavi, F., Hashemy, S. I., Ghadiri, M. K., Stummer, W., & Gorji, A. (2023) · BioFactors · doi:10.1002/biof.1953 · Cited by 19
“Upon administration as a prodrug, 5-ALA is metabolized into an effective and highly fluorescent photosensitizer, protoporphyrin IX (PpIX), in cancer cells.(31) The accumulated PpIX further affects tumor cell proliferation and apoptosis.”
BackgroundMetformin enhances the cytotoxicity of 5-aminolevulinic acid-mediated photodynamic therapy in vitro
Osaki, T., Yokoe, I., Takahashi, K., Inoue, K., Ishizuka, M., Tanaka, T., Azuma, K., Murahata, Y., Tsuka, T., Ito, N., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.6237 · Cited by 21
“5-Aminolevulinic acid (5-ALA) is a precursor of protoporphyrin IX (PpIX), a well-known photosensitizer, and is converted in situ to PpIX via the heme biosynthetic pathway (4).”
Sonodynamic therapy using 5-aminolevulinic acid enhances the efficacy of bleomycin
Osaki, T., Ono, M., Uto, Y., Ishizuka, M., Tanaka, T., Yamanaka, N., Kurahashi, T., Azuma, K., Murahata, Y., Tsuka, T., et al. (2016) · Ultrasonics · doi:10.1016/j.ultras.2016.01.003 · Cited by 20
“In photodynamic therapy (PDT), excited photosensitizers (PSs) contribute to the generation of reactive oxygen species (ROS), resulting in oxidative damage to intracellular macromolecules and ultimately cell death [1,2].”
Sato, T., Yasuzawa, T., Uesaka, A., Izumi, Y., Kamiya, A., Tsuchiya, K., Kobayashi, Y., Kuwahata, M., & Kido, Y. (2014) · Nutrition Research · doi:10.1016/j.nutres.2014.04.013 · Cited by 21
“ring precursor of porphyrin, was used for photodiagnosis and photodynamic therapy as a prodrug, in which the photosensitizer protoporphyrin IX is accumulated in cancer cells [13].”
BackgroundQuirk, B. J., Olasz, E. B., Kumar, S. N., Basel, D., & Whelan, H. T. (2021) · Photobiomodulation Photomedicine and Laser Surgery · doi:10.1089/photob.2020.4957 · Cited by 19
“The Muir group (University of Florida) established cell culture and animal models of NF1 that have been characterized and utilized extensively to examine the cellular and molecular biology of NF1 tumorigenicity.9–11 In collaboration with our group at the Medical College of Wisconsin, inceptive in vitro and in vivo stu…”
BackgroundInfluentialIsolation and initial characterization of human glioblastoma cells resistant to photodynamic therapy
Vilchez, M. L., Rodríguez, L. B., Palacios, R. E., Prucca, C. G., Caverzán, M. D., Caputto, B. L., Rivarola, V. A., & Sanabria, L. N. M. (2020) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2020.102097 · Cited by 17
Sawamura, T., Tanaka, T., Ishige, H., Iizuka, M., Murayama, Y., Otsuji, E., Ohkubo, A., Ogura, S., & Yuasa, H. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922415 · Cited by 21
“If a cancer patient is administered with 5-aminolevulinic acid (ALA) as a precursor of heme, photosensitizing protoporphyrin IX (PPIX) is selectively accumulated in cancer cells, owing to their impaired heme synthesis [5–7].”
BackgroundHexaminolevulinate Blue Light Cystoscopy: A Review of Its Use in the Diagnosis of Bladder Cancer
Yang, L. P. H. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0068-x · Cited by 17
“However, it is hydrophilic at physiological pH and is associated with low lipid solubility and bioavailability [11], thus limiting the ultimate fluorescence yield of protoporphyrin IX [15].”
InfluentialOrganoiridium Photosensitizers Induce Specific Oxidative Attack on Proteins within Cancer Cells
Zhang, P., Chiu, C. K. C., Huang, H., Lam, Y. P. Y., Habtemariam, A., Malcomson, T., Paterson, M. J., Clarkson, G. J., O’Connor, P. B., Chao, H., et al. (2017) · Angewandte Chemie · doi:10.1002/ange.201709082 · Cited by 18
5-Aminolevulinic acid tumor paint and photodynamic therapy for myxofibrosarcoma: an in vitro study
Kenan, S., Liang, H., Goodman, H. J., Jacobs, A. J., Chan, A. Y., Grande, D. A., & Levin, A. S. (2020) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-020-01606-9 · Cited by 17
“Photodynamic therapy (PDT) uses a photosensitizer drug that is activated by a light source to exert cytotoxic activity toward cells [9].”
BackgroundInvestigation of LED-based photodynamic therapy efficiency on breast cancer cells
Kamanlı, A. F., Yıldız, M. Z., Özyol, E., Özkan, A. D., Kucukkara, E. S., & Eskiler, G. G. (2020) · Lasers in Medical Science · doi:10.1007/s10103-020-03061-8 · Cited by 17
Specific Targeting of Melanotic Cells with Peptide Ligated Photosensitizers for Photodynamic Therapy
Bigliardi, P. L., Rout, B., Pant, A., Krishnan‐Kutty, V., Eberlé, A. N., Srinivas, R., Burkett, B. A., & Bigliardi‐Qi, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-15142-w · Cited by 19
Metadata
- Authors
- Wachowska, M., Muchowicz, A., Firczuk, M., Gabrysiak, M., Winiarska, M., Wańczyk, M., Bojarczuk, K., & Golab, J.
- Affiliations
- Medical University of Warsaw (PL)
- Department of Immunology, Centre of Biostructure Research, Medical University of Warsaw, Banacha 1A F Building, 02-097 Warsaw, Poland
- ORCID
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2011-05-19
- Volume
- 16
- Issue
- 5
- Pages
- 4140-4164
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC6263343
- OpenAlex
- W1976436613
- Semantic Scholar
- 4c745297bf1ff574274bed2dbd865f2a7d5cc6ee
- Cited by
- 265
- References
- 161
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 28 · 2023: 19 · 2022: 14 · 2021: 24 · 2020: 36 · 2019: 23 · 2018: 17 · 2017: 24 · 2016: 25 · 2015: 10 · 2014: 13 · 2013: 4 · 2012: 9
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fundacja na rzecz Nauki Polskiej
- Servier
- European Regional Development Fund (POIG. 01.01.02-00-008/08)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Porphyrin Metabolism and Disorders
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- 5-aminolevulinic acid, photodynamic therapy, prodrugs, protoporphyrin IX, photosensitizers, ferrochelatase, heme biosynthesis, cancer therapy, heme oxygenase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.